MPO G-463A Gene Polymorphism and Circulating Matrix Metalloproteinase-9, Myeloperoxidase Levels in Coronary Artery Disease Patients

Objective: Coronary artery disease(CAD) patients living in Elazığ region is to assess the levels of matrix metalloproteinase-9(MMP-9) and myeloperoxidase(MPO), polymorphisms MPO gene. Research Design and Methods: Eighty-eight patients with angiographically diagnosed coronary artery disease between the ages of 18-80 who applied to Department of Cardiology, Faculty of Medicine, Firat University were enrolled in this study. MPO, MMP-9 levels in plasma samples of individuals were determined by enzyme-linked immuno sorbent assay (ELISA) according to the kit procedure. MPO polymorphism was studied using the PCR-RFLP technique. Results: When plasma MPO and MMP-9 levels were compared in the control and CAD groups; MPO levels were statistically significant (p <0.05). MMP-9 levels were not statistically significant. MPO gene polymorphism was not found statistically significant in CAD. Conclusion: MPO gene polymorphism is thought to be associated with greater population populations in CAD and may be used in the future as a biomarker for plasma MPO enzyme levels in CAD.Key words: MPO, coronary artery disease, MMP-9DOI: 10.7176/JHMN/83-0

The protective effects of omega-3 fatty acids on rat testicular tissue

Objectives: In this study, the protective effect of omega-3 fatty acids on testicular tissue was aimed to investigate at biochemical levels.Materials and methods: Totally, 16 adult male Wistar rats were divided into two groups. Rats in Group I were used as control and only saline was given by intragastric gavage. Rats in Group II, 400 mg/kg dose ω-3 fatty acids were given daily by intragastric gavage. At the end of the six-week experimental period, all rats were killed by decapitation. The testicular tissue specimens taken from animals, superoxide dismutase, glutathione peroxidase, malondialdehyde, enzyme activities were measured spectrophotometrically. In addition, blood testosterone levels were examined.Results: In our study, ω-3 fatty acids in rats were given a statistically significant increase in the levels of superoxide dismutase, and glutathione peroxidase a statistically significant decrease in malondialdehyde levels were determined when compared to control group. In addition, ω-3 fatty acids in rats given a statistically significant increase in blood testosterone levels were observed.Conclusion: We concluded that ω-3 fatty acid had favorable effects in rat testis tissue by preventing oxidative damage and increasing the level of testosterone

The Effect of the Serum Amino Acid Levels Thiosemicarbazone Derivatives and its Metal Complexes on Rats

Advers biological activities of Thiosemicarbazone (TSC) and Schiff base (SB) derivatives have been widely studied in rats and in other animal species using different doses, times and routes of administration. To date, no attempt has been made to study alterations occurring in the amino acid profile in the effects of the thiosemicarbazone derivative and its metal complexes on the rats. At this study, the rats were injected subcutaneously with a new thiosemicarbazone and its LH-Zn and LH-Cu complexes (25 mg/kg body weight) and then sacrified after 15th days. The aim of this study was to determine the effect of new compounds on the serum amino acid levels in rats. In the comparision done among groups, it was observed that serum amino acid concentrations were statistically changed (p < 0.05). [Med-Science 2013; 2(2.000): 591-600

Measurement uncertainty in biochemical parameters

Measurement uncertainty is a quality indicator that is used to show the distribution level of a test result in a laboratory. The aim of this study is to calculate the measurement uncertainty of ten biochemical parameters investigated in our laboratory and compare the obtained values with the permissible total error values (% TEa), which various authorities determine for these tests. The measurement uncertainty of glucose, ALT, AST, urea, creatinine, sodium, potassium, albumin, total protein and total cholesterol were investigated in the biochemical auto analyzer (Siemens Advia 2400). Fifty randomly selected 2 level (low and high) internal quality assessment results and external quality assessment of six-month data, the first six months of 2016, were calculated for each test. Nordtest guide was used for the measurement uncertainty calculation. The measurement uncertainties were calculated as 3.9%, 6.72%, 3.4%, 8.06%, 9.06%, 6.08%, 5.02%, 4.98%, 4.96% and 7.22% for glucose, ALT, AST, urea, creatinine, albumin, total protein and total cholesterol, respectively. The calculated measurement uncertainties were found to be lower than the CLIA88 and RiLi-BEAK % TEa values, except for sodium. Calculated % TEa values for creatinine, sodium, total protein and albumin were found to be higher than Fraser % TEa values. A test result or a measurement is not sufficiently effective when reliability is not assessed. Laboratories should calculate the measurement uncertainty for each parameter. They should give the results that do not exceed the targeted % TEa values. Clinicians should be informed about the measurement uncertainties so that they consider it while evaluating patient results. [Med-Science 2018; 7(3.000): 544-7

Stężenie adipocytarnego białka wiążącego kwasy tłuszczowe u pacjentów z chorobą wieńcową i zależności między tym białkiem a innymi biomarkerami

Background and aim: An association between circulating adipocyte fatty acid-binding protein (A-FABP) levels and coronary artery disease (CAD) has been reported. In this case-control study, we investigated the relationship between plasma levels of A-FABP and the severity of CAD in Turkish subjects. We also assessed its relationship to alternative biomarkers. Methods: Two hundred and eighty patients undergoing coronary angiography were enrolled in the study. By means of coronary angiography, the study population was divided into subjects without any angiographically detectable CAD (no vessel disease; n = 88) and individuals with single-vessel disease (n = 65), or double- or triple-vessel disease (n = 127). Lipid concentrations were measured by an autoanalyser and A-FABP, lipoprotein associated phospholipase A2 (Lp-PLA2), oxidised-low density lipoprotein (ox-LDL) and high-sensitivity C-reactive protein (hsCRP) levels by a commercial enzyme-linked immunosorbent assay (ELISA) kit. Results: In our study population, total cholesterol and LDL cholesterol levels did not differ significantly between the groups. Levels of high density lipoprotein cholesterol, A-FABP, Lp-PLA2, ox-LDL and hsCRP were significantly different among groups. The higher levels of A-FABP, Lp-PLA2, ox-LDL and hsCRP levels were shown in patients with double/triple-vessel disease. There was not a significant correlation between A-FABP and other biomarkers in CAD patients. Conclusions: Initially, plasma levels of A-FABP were significantly elevated in CAD patients with double/triple-vessel disease. Our results demonstrated alterations in A-FABP levels with severity of CAD and, therefore, indirectly support the hypothesis of an active role for A-FABP in the pathogenesis of CAD.Wstęp i cel: Opisano związek między stężeniem krążących białek wiążących kwasy tłuszczowe adipocytów (A-FABP) i chorobą wieńcową (CAD). W tym kliniczno-kontrolnym badaniu autorzy przeanalizowali zależności między stężeniem A-FABP w osoczu a ciężkością CAD u osób narodowości tureckiej. Autorzy ocenili również zależności między tym białkiem a innymi biomarkerami. Metody: Do badania włączono 280 chorych poddanych koronarografii. Na podstawie jej wyników pacjentów podzielono na trzy grupy: osoby bez wykrywalnej w koronorografii CAD (bez zmian w naczyniach; n = 88), osoby z chorobą jednonaczyniową (n = 65) i osoby z chorobą dwu- lub trójnaczyniową (n = 127). Stężenia lipidów mierzono za pomocą analizatora automatycznego, a stężenia A-FABP, fosfolipazy A2 związanej z lipoproteinami (Lp-PLA2), utlenionych LDL (ox-LDL) i wysokoczułego białka C-reaktywnego (hsCRP) określano przy użyciu komercyjnego enzymatycznego testu immunoabsorpcyjnego (ELISA). Wyniki: W badanej populacji ani stężenia cholesterolu całkowitego, ani stężenia cholesterolu frakcji LDL nie różniły się znamiennie między grupami. Stężenia cholesterolu frakcji LDL, A-FABP, Lp-PLA2, ox-LDL i hsCRP różniły się istotnie między grupami. Najwyższe stężenia A-FABP, Lp-PLA2, ox-LDL i hsCRP stwierdzono u pacjentów z chorobą dwunaczyniową/trójnaczyniową. U osób z CAD nie wykazano istotnych korelacji między A-FABP a innymi biomarkerami. Wnioski: Stężenie A-FABP w osoczu było istotnie zwiększone u pacjentów z CAD z chorobą dwunaczyniową/trójnaczyniową. Uzyskane w tym badaniu wyniki wykazały zmiany stężenia A-FABP zależne od stopnia ciężkości CAD, co potwierdza pośrednio hipotezę o aktywnej roli A-FABP w patogenezie CAD.

TaqIB and severity of coronary artery disease in the Turkish population: a pilot study

The cholesteryl ester transfer protein (CETP) plays a crucial role in high-density lipoprotein (HDL) metabolism. Genetic variants that alter CETP concentration may cause significant alterations in HDL-cholesterol (HDL-C) concentration. In this case-control study, we analyzed the genotype frequencies of CETP Taq1B polymorphisms in coronary artery disease patients (CAD; n=210) and controls (n=100). We analyzed the role of the CETP Taq1B variant in severity of CAD, and its association with plasma lipids and CETP concentration. DNA was extracted from 310 patients undergoing coronary angiography. The Taq1B polymorphism was genotyped using polymerase chain reaction—restriction fragment length polymorphism (RFLP) analysis. Lipid concentrations were measured by an auto analyzer and CETP level by a commercial enzyme-linked immunosorbent assay (ELISA) kit.  In our study population, the B2 allele frequency was higher in control subjects than patients with single, double or triple vessel disease.  B2B2 genotype carriers had a significantly higher high-density lipoprotein cholesterol (HDL-C) concentration than those with the B1B1 genotype in controls (51.93±9.47versus 45.34±9.93; p<0.05) and in CAD patients (45.52±10.81 versus 40.38±9.12; p<0.05). B2B2 genotype carriers had a significantly lower CETP concentration than those with the B1B1 genotype in controls (1.39±0.58 versus 1.88±0.83; p< 0.05) and in CAD patients (2.04±1.39versus 2.81±1.68; p< 0.05). Our data suggest that the B2 allele is associated with higher concentrations of HDL-C and lower concentrations of CETP, which confer a protective effect on coronary artery disease.  

eNOS Glu298Asp Polymorphism and Endothelial Dysfunction in Patients with and without End-stage Renal Disease

Background: Chronic kidney diseases are known to influence nitric oxide metabolites (NOx) and asymmetric dimethylarginine (ADMA), though the exact mechanism is still poorly understood. Aims: The purpose of the present study was to examine eNOS Glu298Asp gene polymorphism, plasma NOx and ADMA concentration in subjects with and without End-stage Renal Disease. Study Design: Case-control study. Methods: In this study, genotype distributions of Glu298Asp in exon 7 of the eNOS gene polymorphisms in 130 hemodialysis and 64 peritoneal dialysis patients were compared with 92 controls. NOx was measured by using the Griess reaction while arginine, ADMA and SDMA measurements were performed by HPLC. Genotyping for eNOS Glu298Asp polymorphism was detected with the polymerase chain reaction and/or polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. Results: When the genotype frequencies of TT and GT genes were compared between both groups, there was no detected statistically important difference, eventhough a TT genotype frequency was 27 (20.8%) versus 17 (26.6%), GT heterozygote genotype frequency was 52 (40%) versus 22 (34.4%), and GG homozygote genotype frequency was 51 (39.2%) versus 25 (39.1%), respectively (p>0.05). NOx, SDMA and ADMA concentrations were significantly elevated in subjects with hemodialysis patients as compared to their corresponding controls. Whereas nitrite was found to be significantly decreased in the patient with peritoneal dialysis. Conclusion: Not observed any connection between the Glu298Asp polymorphism in the eNOS gene and end-stage Renal Diseases in our study population under different dialysis treatments. However, higher ADMA and SDMA concentrations in subjects with ESRD support the existing hypothesis that NOx overproduction affects endothelial dysfunction. Thus, the reduction of ADMA and SDMA concentrations might play a protective role in ESRD patients